Description du projet
Diagnostic rapide et innovant des maladies infectieuses résistantes aux médicaments
Les infections résistantes aux antimicrobiens figureront parmi les principales causes de décès dans le monde d’ici 2050. La tuberculose multirésistante (TB-MR) est responsable de plus de 240 000 décès par an dans le monde (dont 10 000 en Europe); une grande part est due à l’incapacité de détecter la résistance et la sensibilité aux antibiotiques dans le processus de diagnostic. Le projet Tuberculini, financé par l’UE, évaluera la faisabilité technique et commerciale d’une plateforme unique permettant de diagnostiquer rapidement les maladies infectieuses résistantes aux médicaments, notamment la tuberculose multirésistante, et de proposer un plan de traitement adapté. La plateforme utilise des amorces exclusives pour amplifier l’ADN spécifique des échantillons de patients, puis procède à une analyse par séquençage de nouvelle génération (SNG), et annote les données SNG et détermine la sensibilité ou la résistance sur la base des profils d’ADN via des algorithmes d’apprentissage automatique.
Objectif
Company: Clemedi AG is a Swiss SME, founded in 2019 as a spin-off from the University of Zurich, with the aim to develop in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases. The vision of Clemedi is to support the global battle against antibiotic resistance by developing IVDs that will allow personalized prescription of antibiotics.
Need to address: Antimicrobial resistant infections will be among the world’s leading causes of death by 2050. Multi-drug-resistant tuberculosis (MDR-TB) is a large contributor to death by antimicrobial resistance, with over 240k global mortalities (of which 10k in Europe) per year. Many of these are caused by the inability to detect resistance and antibiotic susceptibility in the diagnostic process.
Solution: Clemedi is developing a unique platform to rapidly diagnose drug-resistant infectious diseases, including MDR-TB, and rapidly provide a matching therapy plan. The platform uses proprietary primers to amplify specific DNA from patient samples, followed by next-generation sequencing (NGS) analysis. Machine-learning algorithms are then used to annotate the NGS data, and determine susceptibility or resistance based on DNA-profiles to provide a focused advice on antibiotic therapy, within 24-48 hours after obtaining a patient’s sample.
Business opportunity: The minimum total addressable market for Clemedi (i.e. every person that needs to be diagnosed for MDR-TB) is valued at €73.7 M. Competitors are companies that also develop IVDs for rapid detection of MDR-TB, such as Hain Lifescience, Cepheid and Becton-Dickinson. The main competitive advantage of Tuberculini is its ability to analyze susceptibility for a significantly larger number of antibiotics (12 vs. 1-5). Only this can positively impact disease management.
Feasibility study: Financial support from the SMEi P1 will be used to assess the technical and commercial feasibility of Tuberculini, Clemedi’s IVD for MDR-TB.
Champ scientifique
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesclinical medicineclinical microbiology
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
CH-8952 SCHLIEREN
Suisse
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.